Celcuity (CELC)
(Delayed Data from NSDQ)
$18.69 USD
-0.10 (-0.53%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $18.93 +0.24 (1.28%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CELC 18.69 -0.10(-0.53%)
Will CELC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CELC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELC
Why Celcuity (CELC) Might Surprise This Earnings Season
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet
CELC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?
Other News for CELC
Celcuity To Participate in Jefferies Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Celcuity (CELC) and Icon (ICLR)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Celcuity Announces Pricing of Underwritten Common Stock Offering
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing